期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

提高嵌合抗原受体T细胞疗效的研究进展：第57届美国血液学会年会报道

Efficacy improvement of chimeric antigen receptor T-cell immunotherapy： reports from the 57th American Society of Hematology annual meeting
原文传递
导出
摘要 如何增强嵌合抗原受体T细胞（CAR-T）效应是CAR-T研制和应用的一个关键问题。文章主要总结第57届美国血液学会（ASH）年会中针对这一问题的研究成果，包括一些信号通路的抑制、联合表达刺激分子、提高靶细胞的抗原性、优化CAR—T治疗前处理方案以及新的CAR-T制作策略等。 How to improve the efficacy of chimeric antigen receptor T-cell （CAR-T） is one of the key points for manufacture and application of CAR-T. In this review, the studies from the 57th American Society of Hematology （ASH） annual meeting regarding to the strategies for optimal CAR-T activity were summarized, including pathway inhibitors, enhancement antigen expression of target cells, optimization of conditioning chemotherapy, as well＇as the novel technology for CAR-T generation.
作者 李扬秋 曾成武
机构地区 暨南大学医学院血液病研究所暨南大学附属第一医院血液科
出处 《白血病．淋巴瘤》 CAS 2016年第1期1-3,11,共4页 Journal of Leukemia & Lymphoma
关键词 嵌合抗原受体T细胞 血液肿瘤 细胞毒活性 信号通路抑制剂 美国血液学 会年会 Chimeric antigen receptor T-cells Hematological malignancy Cytotoxicity Signalingpathway inhibitors American Society of Hematology annual meeting
分类号 R733 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1邹怡新,缪袆,徐卫,李建勇.嵌合抗原受体T细胞疗法在血液病中的应用：第57届美国血液学会年会报道[J].白血病．淋巴瘤,2016,25(1):4-6. 被引量：1
  • 2Urak R, Wang X. Ex vivo AKT inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy [ J ]. Blood ( ASH annual meeting Abstracts ), 2015, 126 ( 21 ) : 3086. 被引量：1
  • 3Perkins MR, Morgan RA. Manufacturing an enhanced CAR T cell product by inhibition of the PI3K/Akt pathway during T cell expansion results in improved in vivo efficacy of anti-BCMA CAR T ceils [ J ]. Blood ( ASH annual meeting Abstracts ), 2015, 126 (21) :1893. 被引量：1
  • 4Ruella M, Wasik MA. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells ( CART19 ) improves engraftment and antitumor responses against mantle cell lymphoma [ J ]. Blood ( ASH annual meeting Abstracts ), 2015, 126 ( 21 ) : 704. 被引量：1
  • 5Foster A, Spencer DM. Expression ofMyD88 / CD40 drives in vivo activation and proliferation of chimeric antigen receptor-modified T ceils that can be effectively regulated by inducible caspase-9 [ J ]. Blood ( ASH annual meeting Abstracts ), 2015, 126 ( 21 ) :851. 被引量：1
  • 6Foster A, Spencer DM. inducible MyD88 / CD40 allows rimiducid- dependent activation to control proliferation and survival of chimeric antigen receptor-modifled T ceils [ J ]. Blood ( ASH annual meeting Abstracts ), 2015, 126( 21 ) :4295. 被引量：1
  • 7Mihara K, Ichinohe T. All-trans retinoic acid and interferon-alpha increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors [ J ]. Blood ( ASH annual meeting Abstracts ), 2015, 126 ( 21 ) : 591. 被引量：1
  • 8Turtle CJ, Maloney DG. Anti-CD19 chimeric antigen receptor- modified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR- T cells and clinical outcomes [ J ]. Blood ( ASH annual meeting Abstracts ) ,2015,126 ( 21 ) : 184. 被引量：1
  • 9Turtle C J, David G, Maloney DG. Addition of fludarabine to eyclophosphamide lymphodepletion improves in vivo expansion of C D 19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphohlastie leukemia [ J ]. Blood ( ASH annual meeting Abstracts ), 2015, 126 ( 21 ) : 3773. 被引量：1
  • 10Bot A, Roberts MR. Cyclophosphamide and fludarabine conditioning chemotherapy induces a key homeostatic eytokine profile in patients prior to CAR T cell therapy [ J ]. Blood (ASH annual meeting Abstracts ). 2015. 126 f 21 ) : 4426. 被引量：1
白血病．淋巴瘤
2016年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部